"Designing Growth Strategies is in our DNA"

Orthobiologics Market Size, Share and Industry Analysis by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics), and Regional Forecast 2019-2026

Region : Global | Published Date: Oct, 2019 | Report ID: FBI100173| Status : Published

 

KEY INDUSTRY INSIGHTS

Play Audio Listen to this report overview

The global orthobiologics market size was valued at USD 5,830.1 Million in 2018 and is projected to reach USD 8,261.6 Million by 2026, exhibiting a CAGR of 4.5% in the forecast period (2019-2026).


The economic burden due to orthopedic injuries and osteoarthritis is increasing at a significant rate. According to the Centers for Disease Control and Prevention (CDC), over 30 Mn people in the U.S. are affected by osteoarthritis, making it a major concern for healthcare providers. This shows that the demand for orthobiologics is likely to augment in the forecast period.


Orthobiologics have considerably impacted orthopedic surgeries. Orthobiologics, which was earlier used for regenerative medicines, has now expanded its area of application to spinal fusion, dental, maxillofacial, cartilage repair, knee arthroscopies and many others, thus impacting the orthobiologics market demand. The increasing demand and rapid adoption of the newly introduced products such as Medtronic’s Infuse, a bone morphogenetic protein, etc., are primary reasons for the surge in the market.


Get comprehensive study about this report by, request a free sample copy


"High demand for viscosupplements to surge the global market"


Viscosupplements are injections of hyaluronic acid, which are directly administered into the joints. Viscosupplements are extensively used in the treatment of knee osteoarthritis, which is one of the major problems among the geriatric population. High product costs, entries of the new manufacturers, and recent marketing approvals are the factors attributed to the expansion of viscosupplements.


Furthermore, improving reimbursement guidelines for viscosupplements are also favoring the viscosupplements segments. Considering the aforementioned factors, the high demand for viscosupplements is anticipated to drive the orthobiologics market growth during the forecast period.


To get details on market share, speak to our analyst




Market Segmentation


Based on the product, the global orthobiologics market segments include viscosupplements, bone growth stimulators, demineralized bone matrix, synthetic bone substitutes, stem cells, allograft, and others. Belonging to the first generation of orthobiologics, viscosupplements dominated the market in 2018 with a share of 32.1% in the global market. Based on applications, the global market segments include spinal fusion, maxillofacial & dental, soft tissue repair, reconstructive & fracture surgery, and others.


Spinal fusion accounted for the highest market share in 2018, owing to the increased use of synthetic matrices and allografts in spine fusion surgeries. Soft tissue repair segment witnessed the highest growth due to the increased cases of sports injuries and demand for orthobiologics for cartilage repair. Based on end user, the global market segments include hospitals, ambulatory surgical centers, and specialty clinics. The rising demand for orthobiologics among these end-users is anticipated to foster the orthobiologics market share in the forecast years.


Regional Analysis


"Growing Trend of Orthopedic Surgery in Outpatient Settings to Favor the Market in North America"


The orthobiologics market in North America was valued at US$ 2,326.2 Mn in 2018 and is estimated to dominate the market throughout the forecast period. Business strategies of leading manufacturers in the U.S., favorable reimbursement policies, increasing prevalence of degenerative bone diseases and growing trend of orthopedic surgeries in outpatient settings are the factors that may boost the orthobiologics market in North America during 2019-2026.


In terms of revenues, Europe is projected to be the second dominant region with a significant share in the global orthobiologics market owing to the new marketing approval for Cingal, a viscosupplements in Europe. Asia Pacific is expected to register the highest CAGR during the forecast period, which is attributable to the increasing demand for viscosupplements in India and rising number of standalone orthopedic clinics. Latin America and the Middle East & Africa are expected to witness a considerable market potential in the forecast period owing to the rising demand for treatment of sports injuries and an increase in government initiatives for awareness of orthobiologics.


North America Orthobiologics Market, 2018

To get geographical overview of this market, request a free sample copy


Key Market Drivers


"Medtronic and Sanofi to lead the Orthobiologics Market"


Medtronic has emerged as the leading player in the global orthobiologics industry, mainly due to the successful launch and rapid adoption for Infuse bone morphogenetic protein. Medtronic is estimated to hold the highest share in the forecast duration owing to the higher cost and strong sales force for Infuse and FDA approval received for the use of Infuse in new spine surgery indication in April 2018. Enabled by these initiatives, the orthobiologics market revenue is likely to spur in the forthcoming years. Other players operating in the global market are DePuy Synthes (Johnson & Johnson Services, Inc.), Stryker, Zimmer Biomet, Sea Spine, Bioventus, RTI Surgical Holdings, Inc., Musculoskeletal Transplant Foundation, Wright Medical Group N.V., and Anika Therapeutics, Inc.


List of Companies Profiled



  • Zimmer Biomet

  • Genzyme Corporation (Sanofi)

  • DePuy Synthes (Johnson & Johnson Services, Inc.)

  • Stryker

  • Medtronic

  • Wright Medical Group N.V.

  • Anika Therapeutics, Inc.

  • SeaSpine

  • Bioventus

  • RTI Surgical Holdings, Inc.

  • Musculoskeletal Transplant Foundation

  • Other players


Report Coverage


The rising number of reconstructive and regenerative surgeries have resulted in increased demand for orthobiologic products. Orthobiologics are the products that are used during surgeries to aid quick healing of orthopedic injuries. Orthobiologics are made from products ranges from growth stimulators to synthetic bone substitutes.


The report provides qualitative and quantitative insights on the orthobiologics industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented based on product type, application, end user, and geography. In terms of product type, the global market is segmented into viscosupplements, bone growth stimulators (Bone Morphogenetic Proteins and Platelet-Derived Growth Factors), demineralized bone matrix (DBM), synthetic bone substitutes, stem cells, allografts, and others.


On the basis of application, the market is categorized into spinal fusion, maxillofacial & dental, soft tissue repair, reconstructive & fracture surgery, and others. The end-users for orthobiologic products include hospitals, ambulatory surgical centres, and specialty clinics. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.


 

To get information on various segments, share your queries with us


Along with this, the report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of soft tissue injuries for key countries, number of spinal fusion surgery for key countries, regulatory scenario in key countries, new product launch, key mergers and acquisitions: recent industry developments, and others.


SEGMENTATION


























ATTRIBUTE



  DETAILS



By Product Type




  • Viscosupplements

  • Bone Growth Stimulators

    • Bone Morphogenetic Proteins (BMP)

    • Platelet-Derived Growth Factors



  • Demineralized Bone Matrix (DBM)

  • Synthetic Bone Substitutes

  • Stem Cells

  • Allografts

  • Others



By Application




  • Spinal Fusion

  • Maxillofacial & Dental

  • Soft Tissue Repair

  • Reconstructive & Fracture Surgery

  • Others



By End User




  • Hospitals

  • Ambulatory Surgical Centers

  • Speciality Clinics



By Geography




  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



Key Industry Developments



  • In March 2019, Bioventus launched OSTEOAMP SELECT Fibers an allograft for spine, foot & ankle, orthopedic and trauma patients, giving surgeons more options for bone healing and remodeling while delivering positive patient outcomes.

  • In March 2019, SEIKAGAKU CORPORATION launched HYLINK a single-injection viscosupplement for the treatment of patients with knee osteoarthritis.

  • In January 2019, Bioventus launched DUROLANE a single-injection joint-fluid for treatment of patients with osteoarthritis.


Frequently Asked Questions

Fortune Business Insights says that the value of the global orthobiologics market USD 5,830.1 Million 2017

The orthobiologics market is projected to reach USD 8,261.6 Million by 2026

The orthobiologics market will grow at a rate of 4.5% CAGR.

Orthobiologics Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2015-2017
  • 133

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X